Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H25ClFN5O3 |
Molecular Weight | 473.928 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC(=O)CN1CCC(CC1)OC2=CC3=C(NC4=CC=CC(Cl)=C4F)N=CN=C3C=C2OC
InChI
InChIKey=DFJSJLGUIXFDJP-UHFFFAOYSA-N
InChI=1S/C23H25ClFN5O3/c1-26-21(31)12-30-8-6-14(7-9-30)33-20-10-15-18(11-19(20)32-2)27-13-28-23(15)29-17-5-3-4-16(24)22(17)25/h3-5,10-11,13-14H,6-9,12H2,1-2H3,(H,26,31)(H,27,28,29)
Molecular Formula | C23H25ClFN5O3 |
Molecular Weight | 473.928 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Sapitinib is an oral, reversible and equipotent inhibitor of EGFR, HER2 and HER3 signalling. The drug was tested in phase II of clinical trials in patients with breast cancer, colorectal cancer, gastric cancer and NSCL carcinoma, however its development for breast cancer therapy seems to be terminated. Sapitinib absorption is rapid and the drug is totally cleared by metabolism with the major routes being oxidation and amine or ether cleavage around the piperidine ring with subsequent glucuronide or sulphate conjugation.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20145185 |
4.0 nM [IC50] | ||
Target ID: CHEMBL1824 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20145185 |
3.0 nM [IC50] | ||
Target ID: CHEMBL5838 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20145185 |
4.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1345 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23589215 |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
SAPITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8049 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23589215 |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
SAPITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/23589215 |
240 mg single, oral dose: 240 mg route of administration: Oral experiment type: SINGLE co-administered: |
SAPITINIB plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer. | 2010 Feb 15 |
|
Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors. | 2013 Aug 8 |
Sample Use Guides
Colorectal cancer: Patients were receiving 160 mg sapitinib tablets, twice daily on days 1-4 of each 2-weekly cycle + FOLFIRI. Breast cancer: Patients were receiving daily anastrozole (1 mg) in combination with sapitinib 20 mg twice daily (bid) or sapitinib 40 mg bid.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24554387
MCF7 and T47D breast cancer cells were treated with sapitinib (1 uM) in combination with estradiol (10−9 M), estrogen deprivation, tamoxifen (10−7 M), or ICI 182,78 (10−7 M).
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:56:48 GMT 2025
by
admin
on
Mon Mar 31 20:56:48 GMT 2025
|
Record UNII |
3499328002
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C129825
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
||
|
NCI_THESAURUS |
C2167
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB128141
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
PRIMARY | |||
|
3499328002
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
PRIMARY | |||
|
9528
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
PRIMARY | |||
|
132986
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
PRIMARY | |||
|
DB12183
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
PRIMARY | |||
|
11488320
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
PRIMARY | |||
|
100000153842
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
PRIMARY | |||
|
CHEMBL2408045
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
PRIMARY | |||
|
DTXSID50233942
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
PRIMARY | |||
|
848942-61-0
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
PRIMARY | |||
|
C77887
Created by
admin on Mon Mar 31 20:56:48 GMT 2025 , Edited by admin on Mon Mar 31 20:56:48 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> INHIBITOR |
COMPETITIVE INHIBITOR
IC50
|
||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> INHIBITOR |
COMPETITIVE INHIBITOR
IC50
|
||
|
TARGET -> INHIBITOR |
COMPETITIVE INHIBITOR
IC50
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |